A

Aquestive Therapeutics Inc
NASDAQ:AQST

Watchlist Manager
Aquestive Therapeutics Inc
NASDAQ:AQST
Watchlist
Price: 4.6946 USD -2.8% Market Closed
Market Cap: 427.5m USD
Have any thoughts about
Aquestive Therapeutics Inc?
Write Note

Intrinsic Value

AQST's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one AQST stock under the Base Case scenario is 2.0795 USD. Compared to the current market price of 4.6946 USD, Aquestive Therapeutics Inc is Overvalued by 56%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

AQST Intrinsic Value
2.0795 USD
Overvaluation 56%
Intrinsic Value
Price
A
Worst Case
Base Case
Best Case

Valuation Backtest
Aquestive Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for AQST cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about AQST?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Pharmaceuticals Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Aquestive Therapeutics Inc

Provide an overview of the primary business activities
of Aquestive Therapeutics Inc.

What unique competitive advantages
does Aquestive Therapeutics Inc hold over its rivals?

What risks and challenges
does Aquestive Therapeutics Inc face in the near future?

Summarize the latest earnings call
of Aquestive Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Aquestive Therapeutics Inc.

Provide P/S
for Aquestive Therapeutics Inc.

Provide P/E
for Aquestive Therapeutics Inc.

Provide P/OCF
for Aquestive Therapeutics Inc.

Provide P/FCFE
for Aquestive Therapeutics Inc.

Provide P/B
for Aquestive Therapeutics Inc.

Provide EV/S
for Aquestive Therapeutics Inc.

Provide EV/GP
for Aquestive Therapeutics Inc.

Provide EV/EBITDA
for Aquestive Therapeutics Inc.

Provide EV/EBIT
for Aquestive Therapeutics Inc.

Provide EV/OCF
for Aquestive Therapeutics Inc.

Provide EV/FCFF
for Aquestive Therapeutics Inc.

Provide EV/IC
for Aquestive Therapeutics Inc.

Show me price targets
for Aquestive Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Aquestive Therapeutics Inc?

How accurate were the past Revenue estimates
for Aquestive Therapeutics Inc?

What are the Net Income projections
for Aquestive Therapeutics Inc?

How accurate were the past Net Income estimates
for Aquestive Therapeutics Inc?

What are the EPS projections
for Aquestive Therapeutics Inc?

How accurate were the past EPS estimates
for Aquestive Therapeutics Inc?

What are the EBIT projections
for Aquestive Therapeutics Inc?

How accurate were the past EBIT estimates
for Aquestive Therapeutics Inc?

Compare the revenue forecasts
for Aquestive Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Aquestive Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Aquestive Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Aquestive Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Aquestive Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Aquestive Therapeutics Inc with its peers.

Analyze the financial leverage
of Aquestive Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Aquestive Therapeutics Inc.

Provide ROE
for Aquestive Therapeutics Inc.

Provide ROA
for Aquestive Therapeutics Inc.

Provide ROIC
for Aquestive Therapeutics Inc.

Provide ROCE
for Aquestive Therapeutics Inc.

Provide Gross Margin
for Aquestive Therapeutics Inc.

Provide Operating Margin
for Aquestive Therapeutics Inc.

Provide Net Margin
for Aquestive Therapeutics Inc.

Provide FCF Margin
for Aquestive Therapeutics Inc.

Show all solvency ratios
for Aquestive Therapeutics Inc.

Provide D/E Ratio
for Aquestive Therapeutics Inc.

Provide D/A Ratio
for Aquestive Therapeutics Inc.

Provide Interest Coverage Ratio
for Aquestive Therapeutics Inc.

Provide Altman Z-Score Ratio
for Aquestive Therapeutics Inc.

Provide Quick Ratio
for Aquestive Therapeutics Inc.

Provide Current Ratio
for Aquestive Therapeutics Inc.

Provide Cash Ratio
for Aquestive Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Aquestive Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Aquestive Therapeutics Inc?

What is the current Free Cash Flow
of Aquestive Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Aquestive Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Aquestive Therapeutics Inc

Current Assets 104m
Cash & Short-Term Investments 89.9m
Receivables 6m
Other Current Assets 8.1m
Non-Current Assets 13.6m
PP&E 9.4m
Other Non-Current Assets 4.2m
Current Liabilities 13.9m
Accounts Payable 5.7m
Accrued Liabilities 6.1m
Other Current Liabilities 2.1m
Non-Current Liabilities 139.2m
Long-Term Debt 30m
Other Non-Current Liabilities 109.2m
Efficiency

Earnings Waterfall
Aquestive Therapeutics Inc

Revenue
58.4m USD
Cost of Revenue
-18.4m USD
Gross Profit
40m USD
Operating Expenses
-55.2m USD
Operating Income
-15.2m USD
Other Expenses
-10.5m USD
Net Income
-25.7m USD

Free Cash Flow Analysis
Aquestive Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

AQST Profitability Score
Profitability Due Diligence

Aquestive Therapeutics Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Gross Profit
ROIC is Increasing
Exceptional ROE
45/100
Profitability
Score

Aquestive Therapeutics Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.

AQST Solvency Score
Solvency Due Diligence

Aquestive Therapeutics Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Negative Net Debt
Long-Term Solvency
46/100
Solvency
Score

Aquestive Therapeutics Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AQST Price Targets Summary
Aquestive Therapeutics Inc

Wall Street analysts forecast AQST stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AQST is 9.6263 USD with a low forecast of 5.555 USD and a high forecast of 15.75 USD.

Lowest
Price Target
5.555 USD
18% Upside
Average
Price Target
9.6263 USD
105% Upside
Highest
Price Target
15.75 USD
235% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for AQST?

Click here to dive deeper.

Dividends

Aquestive Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for AQST is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Aquestive Therapeutics Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

427.5m USD

Dividend Yield

0%

Description

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. The company is headquartered in Warren, New Jersey and currently employs 157 full-time employees. The company went IPO on 2018-07-25. The firm is engaged in developing orally administered products to deliver molecules, providing alternatives to care therapies. The company is engaged in advancing a late-stage product pipeline focused on treating diseases of the central nervous system (CNS), and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. The firm's CNS portfolio, which is focused on epilepsy includes Sympazan and Libervant. The active programs in its complex molecule pipeline portfolio are: AQST-109-SF, AQST-108-SF, and AQST-108-SF. Its PharmFilm technology develops medicines that offer non-invasive delivery, customized suitability for patients with dysphagia, or trouble swallowing, can be administered without water and ensures consistent therapeutic dosing. PharmFilm is comprised of polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs) and excipients in place.

Contact

NEW JERSEY
WARREN
30 Technology Dr
+19089411900.0
aquestive.com

IPO

2018-07-25

Employees

157

Officers

CEO, President & Director
Mr. Daniel Barber
Chief Financial Officer
Mr. A. Ernest Toth Jr.
General Counsel, Chief Compliance Officer & Corporate Secretary
Ms. Lori J. Braender BSBA, Esq., J.D.
Chief Operating Officer
Ms. Cassie Jung
Chief Innovation & Technology Officer
Mr. Alexander Mark Schobel
Chief Science Officer
Dr. Stephen Wargacki Ph.D.
Show More
Senior Vice President of Sales & Marketing
Ms. Sherry Korczynski
Senior Vice President of Information Technology & Human Resources
Mr. Peter E. Boyd
Chief Medical Officer
Dr. Carl N. Kraus M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one AQST stock?

The intrinsic value of one AQST stock under the Base Case scenario is 2.0795 USD.

Is AQST stock undervalued or overvalued?

Compared to the current market price of 4.6946 USD, Aquestive Therapeutics Inc is Overvalued by 56%.

Back to Top